KRAS and neoplasm: Genetic abnormalities coexisting with KRAS gene mutations may be related to the tumor microenvironment, the capacity of the immune system’s anticancer response, or the efficacy of the treatment: chemotherapy, immunotherapy or even molecularly targeted therapies.